PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Authors: James P Buteau, Andrew Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, Roslyn J. Francis, Alison Y. Zhang, Andrew M. Scott, Sze-Ting Lee, Arun Azad, Margaret McJannett, Martin R. Stockler, Scott Williams, Ian D. Davis, Michael S. Hofman, Tim Akhurst, Ramin Alipour, Arun Azad, Patricia Banks, Alexis Beaulieu, James P Buteau, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang, Sonia Yip, Alison Y. Zhang - The Lancet 2022 cited by 266